Hydrophilic Ester-Bearing Chlorogenic Acid Binds to a Novel Domain to Inhibit Xanthine Oxidase

Abstract

Caffeic acid is a xanthine oxidase (XO) inhibitor that binds to the molybdopterin region of its active site. Caffeic acid phenethyl ester (CAPE) has higher hydrophobicity and exhibits stronger inhibition potency toward XO. Chlorogenic acid is a quinyl ester of caffeic acid that has increased hydrophilicity and also shows stronger XO inhibitory activity compared with caffeic acid. Caffeic acid and CAPE showed competitive inhibition against XO, whereas chlorogenic acid displayed mixed-type inhibition, implying that it binds to sites other than the active site. Structure-based molecular modeling was performed to account for the different binding characteristics of the hydrophobic and hydrophilic esters of caffeic acid. Chlorogenic acid showed weak binding to the molybdopterin region of XO, while it more strongly bound the flavin adenine dinucleotide region than it did the molybdopterin region. These results provide the basis for interactions of caffeic acid analogues with XO via various binding domains.

Key words

caffeic acid - chlorogenic acid - FAD - molecular modeling - molybdopterin - xanthine oxidase

References

• 1 Harrison R. Physiological roles of xanthine oxidoreductase.  Drug Metab Rev. 2004;  36 363-375
• 2 Okamoto K, Matsumoto K, Hille R, Eger B T, Pai E F, Nishino T. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition.  Proc Natl Acad Sci USA. 2004;  101 7931-7936
• 3 Enroth C, Eger B T, Okamoto K, Nishino T, Pai E F. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion.  Proc Natl Acad Sci USA. 2000;  97 10723-10728
• 4 Wu Y, Hu S. Direct electron transfer of xanthine oxidase and its catalytic reduction to nitrate.  Anal Chim Acta. 2007;  602 181-186
• 5 Godber B L, Doel J J, Sapkota G P, Blake D R, Stevens C R, Eisenthal R, Harrison R. Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase.  J Biol Chem. 2000;  275 7757-7763
• 6 Schroder K, Vecchione C, Jung O, Schreiber J G, Shiri-Sverdlov R, van Gorp P J, Busse R, Brandes R P. Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet.  Free Radic Biol Med. 2006;  41 1353-1360
• 7 Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.  Pharmacol Rev. 2006;  58 87-114
• 8 Feig D I, Soletsky B, Johnson R J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.  JAMA. 2008;  300 924-932
• 9 George J, Struthers A D. The role of urate and xanthine oxidase inhibitors in cardiovascular disease.  Cardiovasc Ther. 2008;  26 59-64
• 10 Bomalaski J S, Clark M A. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.  Curr Rheumatol Rep. 2004;  6 240-247
• 11 Lin C M, Chen C T, Lee H H, Lin J K. Prevention of cellular ROS damage by isovitexin and related flavonoids.  Planta Med. 2002;  68 365-367
• 12 Lin H C, Tsai S H, Chen C S, Chang Y C, Lee C M, Lai Z Y, Lin C M. Structure-activity relationship of coumarin derivatives on xanthine oxidase-inhibiting and free radical-scavenging activities.  Biochem Pharmacol. 2008;  75 1416-1425
• 13 Lin C M, Chen C S, Chen C T, Liang Y C, Lin J K. Molecular modeling of flavonoids that inhibits xanthine oxidase.  Biochem Biophys Res Commun. 2002;  294 167-172
• 14 Okamoto K, Eger B T, Nishino T, Kondo S, Pai E F. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.  J Biol Chem. 2003;  278 1848-1855
• 15 Fukunari A, Okamoto K, Nishino T, Eger B T, Pai E F, Kamezawa M, Yamada I, Kato N. Y‐700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.  J Pharmacol Exp Ther. 2004;  311 519-528
• 16 Chang Y C, Lee F W, Chen C S, Huang S T, Tsai S H, Huang S H, Lin C M. Structure-activity relationship of C6–C3 phenylpropanoids on xanthine oxidase-inhibiting and free radical-scavenging activities.  Free Radic Biol Med. 2007;  43 1541-1551
• 17 Morris G M, Goodsell D S, Halliday R S, Huey R, Hart W E, Belew R K, Olson A J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function.  J Comput Chem. 1998;  19 1639-1662
• 18 Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity – a rapid access to atomic charges.  Tetrahedron. 1980;  36 3219-3228
• 19 Bonita J S, Mandarano M, Shuta D, Vinson J. Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies.  Pharmacol Res. 2007;  55 187-198
• 20 Bose J S, Gangan V, Jain S K, Manna S K. Novel caffeic acid ester derivative induces apoptosis by expressing fasl and downregulating NF-KappaB: potentiation of cell death mediated by chemotherapeutic agents.  J Cell Physiol. 2009;  218 653-662
• 21 McCord J M. Oxygen-derived free radicals in postischemic tissue injury.  N Engl J Med. 1985;  312 159-163
• 22 Hille R, Nishino T. Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase.  FASEB J. 1995;  9 995-1003
• 23 Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX‐051.  J Nippon Med Sch. 2008;  75 2-3
• 24 Pauff J M, Zhang J, Bell C E, Hille R. Substrate orientation in xanthine oxidase: crystal structure of enzyme in reaction with 2-hydroxy-6-methylpurine.  J Biol Chem. 2008;  283 4818-4824
• 25 Porter D J. Xanthine oxidase-catalyzed reductive debromination of 6-(bromomethyl)-9H-purine with concomitant covalent modification of the FAD prosthetic group.  J Biol Chem. 1990;  265 13540-13546